Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB11 | A5LHX3 | 1/20 | 0.40 |
| ▸ | PSMA7 | O14818 | 1/20 | 0.40 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.40 |
| ▸ | PSMA1 | P25786 | 1/20 | 0.40 |
| ▸ | PSMA2 | P25787 | 1/20 | 0.40 |
| ▸ | PSMA3 | P25788 | 1/20 | 0.40 |
| ▸ | PSMA4 | P25789 | 1/20 | 0.40 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.40 |
| ▸ | PSMB9 | P28065 | 1/20 | 0.40 |
| ▸ | PSMA5 | P28066 | 1/20 | 0.40 |
| ▸ | PSMB4 | P28070 | 1/20 | 0.40 |
| ▸ | PSMB6 | P28072 | 1/20 | 0.40 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.40 |
| ▸ | PSMB10 | P40306 | 1/20 | 0.40 |
| ▸ | PSMB3 | P49720 | 1/20 | 0.40 |
| ▸ | PSMB2 | P49721 | 1/20 | 0.40 |
| ▸ | PSMA6 | P60900 | 1/20 | 0.40 |
| ▸ | PSMA8 | Q8TAA3 | 1/20 | 0.40 |
| ▸ | PSMB7 | Q99436 | 1/20 | 0.40 |
| ▸ | GCK | P35557 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3130090 | 1.00 | PSMB11 (0.40) | PSMB11PSMA7PSMB1PSMA1PSMA2 | |
| SCHEMBL3131118 | 0.89 | GCK (0.39) | PSMB11PSMA7PSMB1PSMA1PSMA2 | |
| SCHEMBL3133787 | 0.87 | GCK (0.38) | PSMB11PSMA7PSMB1PSMA1PSMA2 | |
| SCHEMBL3136843 | 0.85 | SMN1; SMN2 (0.43) | PSMB11PSMA7PSMB1PSMA1PSMA2 | |
| SCHEMBL3131232 | 0.84 | CCR2 (0.43) | GCKCCR2GPR88 | |
| SCHEMBL3131241 | 0.84 | CCR2 (0.43) | GCKCCR2GPR88 | |
| SCHEMBL3131217 | 0.79 | PYGL (0.39) | GCKSMN1; SMN2CCR2ALDH1A1KDM4E | |
| SCHEMBL3132771 | 0.79 | GCK (0.40) | GCKSMN1; SMN2TP53GAAGPR88 | |
| SCHEMBL3134997 | 0.78 | ALDH1A1 (0.44) | ALDH1A1KDM4EGPR88 | |
| SCHEMBL3135014 | 0.78 | ALDH1A1 (0.44) | ALDH1A1KDM4EGPR88 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7807686-B2 | 2-(4-oxo-4H-quinazolin-3-yl)acetamides and their use as vasopressin V3 antagonists | N.V. ORGANON (NL) | 2010-10-05 | — | — | US | disclosed |
| US-7807686-B2 | 2-(4-oxo-4H-quinazolin-3-yl)acetamides and their use as vasopressin V3 antagonists | N.V. ORGANON (NL) | 2010-10-05 | — | — | US | disclosed |
| US-7807686-B2 | 2-(4-oxo-4H-quinazolin-3-yl)acetamides and their use as vasopressin V3 antagonists | N.V. ORGANON (NL) | 2010-10-05 | — | — | US | disclosed |
| EP-1861380-B1 | 2-(4-OXO-4H-QUINAZOLIN-3-YL)ACETAMIDES AND THEIR USE AS VASOPRESSIN V3 ANTAGONISTS | ORGANON NV (NL) | 2010-07-07 | — | — | EP | disclosed |
| EP-1861380-B1 | 2-(4-OXO-4H-QUINAZOLIN-3-YL)ACETAMIDES AND THEIR USE AS VASOPRESSIN V3 ANTAGONISTS | ORGANON NV (NL) | 2010-07-07 | — | — | EP | disclosed |
| US-20080214553-A1 | 2-(4-Oxo-4H-Quinazolin-3-Yl) Acetamides and Their Use as Vasopressin V3 Antagonists | MERCK SHARP & DOHME B.V. (NL) | 2008-09-04 | — | — | US | disclosed |
| US-20080214553-A1 | 2-(4-Oxo-4H-Quinazolin-3-Yl) Acetamides and Their Use as Vasopressin V3 Antagonists | MERCK SHARP & DOHME B.V. (NL) | 2008-09-04 | — | — | US | disclosed |
| US-20080214553-A1 | 2-(4-Oxo-4H-Quinazolin-3-Yl) Acetamides and Their Use as Vasopressin V3 Antagonists | MERCK SHARP & DOHME B.V. (NL) | 2008-09-04 | — | — | US | disclosed |
| EP-1861380-A1 | 2-(4-OXO-4H-QUINAZOLIN-3-YL)ACETAMIDES AND THEIR USE AS VASOPRESSIN V3 ANTAGONISTS | N.V. Organon (NL) | 2007-12-05 | — | — | EP | disclosed |
| WO-2006095014-A1 | 2- (4-0X0-4H-QUINAZ0LIN-3-YL) ACETAMIDES AND THEIR USE AS VASOPRESSIN V3 ANTAGONISTS | N.V. ORGANON (NL) | 2006-09-14 | — | — | WO | disclosed |
| WO-2006095014-A1 | 2- (4-0X0-4H-QUINAZ0LIN-3-YL) ACETAMIDES AND THEIR USE AS VASOPRESSIN V3 ANTAGONISTS | N.V. ORGANON (NL) | 2006-09-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214553-A1 | 2-(4-Oxo-4H-Quinazolin-3-Yl) Acetamides and Their Use as Vasopressin V3 Antagonists | AVPR2, AVPR1A, AVPR1B | PSMB11 3118/4885PSMA7 3392/4885PSMB1 3550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.